8-K: Y-mAbs Therapeutics Enters $35 Million Equity Distribution Agreement with Oppenheimer & Co. Inc.

Y-mAbs Therapeutics has entered into an equity distribution agreement with Oppenheimer & Co. Inc. to sell up to $35 million of its common stock through an 'at the market' offering.

Summary

• Y-mAbs Therapeutics, Inc. has entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc., effective March 4, 2025.
• Under the agreement, Y-mAbs may offer and sell its common stock from time to time through Oppenheimer & Co. Inc., acting as the sales agent.
• The company may offer and sell common stock having aggregate sales proceeds of up to $35.0 million.
• Sales will be made through an 'at the market' offering as defined in Rule 415(a)(4) under the Securities Act of 1933.
• Oppenheimer & Co. Inc. will use commercially reasonable efforts to sell the common stock based on instructions from Y-mAbs, which may include price, time, or size limits.
• Y-mAbs will pay Oppenheimer & Co. Inc. a commission of up to 3.0% of the gross proceeds from any sale of common stock.
• The company is not obligated to make any sales of common stock under the Sales Agreement.
• The offering of shares will terminate as provided in the Sales Agreement.
• The common stock is being offered and sold pursuant to an effective shelf registration statement on Form S-3 (Registration Statement No. 333-271006) and a prospectus supplement dated March 4, 2025.
• Cooley LLP has provided an opinion regarding the shares to be sold under the Sales Agreement.

Sentiment

Score: 6

Explanation: The announcement is neutral to slightly positive. It provides the company with financial flexibility but also introduces potential dilution for existing shareholders.

Positives

• Y-mAbs gains flexibility to raise capital through 'at the market' offerings.
• The company retains control over the timing and pricing of stock sales.
• The agreement provides access to Oppenheimer & Co. Inc.'s sales expertise and distribution network.

Negatives

• The company will incur commissions of up to 3.0% on gross proceeds from sales.
• There is no guarantee that the company will be able to sell all $35 million of stock.
• The offering may dilute existing shareholders' equity.

Risks

• Market conditions may affect the company's ability to sell shares at desired prices.
• The offering could exert downward pressure on the company's stock price.
• Failure to comply with the terms of the Sales Agreement could result in termination.

Future Outlook

The company may offer and sell its common stock from time to time through the Sales Agent, but is not obligated to make any sales.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech sector, to raise capital opportunistically. This allows companies to take advantage of favorable market conditions without the need for a traditional underwritten offering.

Comparison to Industry Standards

• The commission rate of up to 3.0% is within the typical range for 'at the market' offerings.
• Similar agreements are common among biotech companies seeking flexible financing options, for example, XOMA Corporation has used similar ATM offerings.
• The size of the offering, $35 million, is relatively modest, suggesting a targeted approach to capital raising.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The company's financial position could be strengthened by the additional capital.
• The company will pay commissions to Oppenheimer & Co. Inc., impacting profitability.

Next Steps

• Y-mAbs will decide on the timing and amount of common stock to be sold through Oppenheimer & Co. Inc.
• Oppenheimer & Co. Inc. will execute sales based on instructions from Y-mAbs.
• The company will file required prospectus supplements with the SEC.

Key Dates